生物制药公司Madrigal Pharmaceuticals, Inc.（纳斯达克股票代码：MDGL）今日盘中股价大跌5.73%，引起市场广泛关注。这一显著跌幅出现在公司发布2025年第一季度财报之后，尽管财报数据优于分析师预期。
根据公司公布的财报，截至3月31日的季度调整后每股亏损为3.32美元，好于13位分析师平均预期的每股亏损3.69美元。公司营收达到1.3725亿美元，同样超过分析师预期的1.1376亿美元。然而，尽管业绩超出预期，Madrigal Pharmaceuticals本季度仍录得7324万美元的亏损。
股价下跌似乎与财报数据相悖，这可能反映出投资者对公司长期财务状况的担忧。尽管公司业绩优于预期，但持续的亏损可能引发了市场对其未来盈利能力的质疑。此外，投资者可能对公司的表现有更高期望，导致即使是相对积极的财报也未能满足市场预期。分析师对该公司的平均评级仍为"买入"，12个月目标价中位数为405.00美元，这与当前股价走势形成鲜明对比，凸显了市场情绪的复杂性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.